Yi Lin (@YiLinMDPhD) ranks #20 among US multiple myeloma KOLs on X in 2026, by engagement from fellow physicians. 6 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: DART. CMS Open Payments lists $74,668 in 2025 general payments.
At a Glance
- 1 posts naming a trial since ASH 2025
- 1 trials discussed by name
- Multiple Myeloma: US #20 · 6 physicians engaged
- CMS Open Payments lists $74,668 in 2025 general payments.
This Month
What Yi Lin has posted in the last 30 days. Updated November 11, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Peer Engagement Score | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|---|
| Multiple Myeloma | #20 | — | 43/100 | 6 | 12 | Full ranking |
What Colleagues Are Saying About Yi Lin
2026 posts by fellow physicians that mention @YiLinMDPhD, quoted word for word.
OK here it is. Finally. My #ASH25 algorithm for Relapsed Myeloma: First Relapse. Discussed with @YiLinMDPhD @myelomaMD Give comments. I’m willing to adjust it based on your insights. https://t.co/uP8RFXIKYU
And with it, finally a new graphic to use for the different BCMA CAR-T therapies as opposed to the same one that all of you at #IMS26 can pick out from a mile away 👏 Congrats @MJFzeta et al on @NEJM paper and to @YiLinMDPhD for this very nice anito-cel editorial! https://t.co/isSV4RJL4D https://t.co/uPou1q22Cy
Wonderful editorial by @YiLinMDPhD accompanying the promising phase I results of anito-cel on the heels of #IMS26 https://t.co/QK4bgUYWLJ Lack of binding to claudin-9 may spare the risk of IEC colitis noted with cilta-cel. Faster off rate due to the smaller synthetic ddBCMA
Trials Yi Lin Discussed since ASH 2025
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| DART | 1 | — | Sep 24, 2026 |
Yi Lin on DART
Happening soon! Grab lunch & come to Alsh room to hear @christoscha presents first report on senolytics to improve #mmsm CAR-T outcome. #IMS26 DART study funded by #NCI @MayoCancerCare Myeloma SPORE @MegVoda @nadineabdal @Leif_Bergsagel @Myeloma_mSMART https://t.co/z9zMCKKRq8
Yi Lin’s Most-Engaged Posts since ASH 2025
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
T cell fitness is important for #CART Can mitochondria modulation improve #CART therapy #lymsm? Come talk to Dr. Jackie Turner #AACR26 poster session this afternoon @PanwenW @pattymondello @MayoCancerCare @MayoMN_IMRES https://t.co/HNP7QolVo9 https://t.co/VgCTGOApDM
Happening now, Dr. Melinda Tan shares our finding on metabolic profiles of immune cells associated with clinical response to #CART #lymsm #AACR26 @MayoCancerCare https://t.co/9W123Fjipy https://t.co/4FGYy6Y0wY
Afternoon poster session kick off now #AACR26! Find out #mmsm cell plasticity & senescence as a mechanism of resistance to #BsAb & #CART by undergraduate superstar Sofia Arbelaez @Yale https://t.co/Vjn1q8FpPg & @christoscha @MegVoda https://t.co/b1fXWBU2BV @MayoCancerCare https://t.co/uayIMMLqfa
Last poster session #AACR26 Check out spatial transcriptime analysis by @LFonkoua from phase II trial #HCC treated with combination radiation, dendritic cells, atezolizumab & avastin. Dramatic changes associated with clinical efficacy. @MayoCancerCare https://t.co/xKGXFUF99W https://t.co/vyM0KzsSU3
Last poster session #AACR26. Check out work from Dr. Jane Zhu lab on GD2-targeting monocytes/macrophages, presented by Ke-En Tan. What are relevant co-signaling for CAR-monocytes? Translation for in vivo therapy @MayoCancerCare @SaiYerneni @MiraKohorstMD https://t.co/qEBMcwaKeu https://t.co/oyRXpAj732
Industry Payments
CMS Open Payments · 2025 general payments
$74,668 across 42 payments